Roche is discontinuing two Phase III clinical studies of crenezumab after an independent interim analysis concluded the anti-beta amyloid monoclonal antibody is unlikely to meet the studies’ primary endpoints, news that continues a long-line of clinical trial disappointments in this therapeutic sector.
Crenezumab was being developed in collaboration with the originator, the Swiss biotech, AC Immune SA, and the failure is...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)